BurtonLasaterScottMD

PubMed

• Characterizing differences in retinal and choroidal microvasculature and structure in individuals with Huntington's Disease compared to healthy controls: A cross-secti...
  Joseph, S., Haystead, A., Hemesath, A., Allen, A., Kundu, A., Ma, J., Agrawal, R., Gunasan, V., Stinnett, S., Robbins, C., Scott, B., Moore, K., Grewal, D., Fekrat, S.> ;Plos One. 2024 Jan 1
• 1 citations
  Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp.
  Noreen Bukhari-Parlakturk, Michael W Lutz, Hussein R Al-Khalidi, Shakthi Unnithan, Joyce En-Hua Wang, Burton Scott, Pichet Termsarasab, Lawrence G Appelbaum, Nicole Ca...> ;Movement Disorders. 2023 Jan 1
• 6 citations
  Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S.
  Kyle T Mitchell, Stephen L Schmidt, Jeffrey W Cooney, Warren M Grill, Jennifer Peters, Shervin Rahimpour, Hui-Jie Lee, Sin-Ho Jung, Sneha Mantri, Burton Scott, Shivana...> ;Neurosurgery. 2022 Jul 1
• 74 citations
  Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
  Michael A. Schwarzschild, Alberto Ascherio, Cindy Casaceli, Gary C. Curhan, Rebecca Fitzgerald, Cornelia Kamp, Codrin Lungu, Eric A. Macklin, Kenneth Marek, Dariush Mo...> ;JAMA. 2021 Sep 14
• Clinical Reasoning: A 55-Year-Old Man With Odd Behavior and Abnormal Movements.
  Paul McIntosh, Burton L. Scott> ;Neurology. 2021 Aug 16
• 6 citations
  Mindfulness based stress reduction in people with Parkinson's disease and their care partners.
  Deepal P Shah-Zamora, Allison M. Allen, Lacy Rardin, Margaret Ivancic, Katie Durham, Patrick Hickey, Jeffrey W. Cooney, Burton L. Scott, Sneha Mantri> ;Complementary Therapies in Clinical Practice. 2021 Mar 31
• 9 citations
  Identifying Peripapillary Radial Capillary Plexus Alterations in Parkinson's Disease Using OCT Angiography.
  Cason B. Robbins, Dilraj S. Grewal, Atalie C. Thompson, Srinath Soundararajan, Stephen P. Yoon, Burton L. Scott, Sharon Fekrat, Polascik, B., Bryce W Polascik> ;Ophthalmology. Retina. 2021 Mar 11
• 78 citations
  Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease.
  Cason B. Robbins, Atalie C. Thompson, Paramjit K Bhullar, Hui Yan Koo, Rupesh Agrawal, Srinath Soundararajan, Stephen P. Yoon, Burton L. Scott, Dilraj S. Grewal, Sharo...> ;JAMA Ophthalmology. 2021 Feb 1
• 73 citations
  Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
  Tanya Simuni, Brian K. Fiske, Kalpana Merchant, Christopher S. Coffey, Elizabeth A. Klingner, Chelsea Caspell-Garcia, David-Erick Lafontant, Helen Matthews, Richard K....> ;JAMA Neurology. 2021 Mar 1
• 29 citations
  Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
  Samuel Frank, David Stamler, Elise Kayson, Daniel O. Claassen, Amy Colcher, Charles S. Davis, Andrew P. Duker, Shirley Eberly, Lawrence Elmer, Erin Furr-Stimming, Mark...> ;JAMA Neurology. 2017 Aug 1
• 85 citations
  A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
  Andrew McGarry, Michael P. McDermott, Karl Kieburtz, Elisabeth A. deBlieck, Flint Beal, Karen Marder, Christopher A. Ross, Ira Shoulson, Peter R. Gilbert, William Mall...> ;Neurology. 2017 Jan 10
• 3 citations
  Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease.
  Patrick Hickey, Maragatha Kuchibhatla, Burton L. Scott, Lisa Gauger, Mark Stacy> ;Journal of Parkinson's Disease. 2017 Jan 1
• 57 citations
  Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for Dystonia
  , , , , , , , , , , , , , , , , , , , > ;Neuron. 2016 Dec 21
• 140 citations
  Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial
  Samuel Frank, Claudia M. Testa, David Stamler, Elise Kayson, Charles S. Davis, Mary Edmondson, Shari Kinel, Blair R. Leavitt, David Oakes, Christine O'Neill, Christina...> ;JAMA. 2016 Jul 5
• 12 citations
  Linkage of familial essential tremor to chromosome 5q35
  James E. Hicks, Ioanna Konidari, Burton L. Scott, Jeffrey M. Stajich, Allison E. Ashley-Koch, John R. Gilbert, William K. Scott> ;Movement Disorders. 2016 Jul 1
• 163 citations
  Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
  Tanya Simuni, Karl Kieburtz, Barbara C. Tilley, Jordan J. Elm, Bernard Ravina, Debra Babcock, Marina E. Emborg, Robert A. Hauser, Cornelia Kamp, John C. Morgan, G. Web...> ;The Lancet. Neurology. 2015 Aug 1
• 35 citations
  A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.
  K. Kieburtz, Georg Bernhard Landwehrmeyer, Merit Cudkowicz, E. R. Dorsey, Andrew Feigin, Vicki Hunt, Elise Kayson, Michael P. McDermott, S Noonberg, W Seitz, Paola Sol...> ;JAMA Neurology. 2013 Jan 1
• 360 citations
  Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.
  Todd L. Edwards, William K. Scott, Cherylyn Almonte, Amber Burt, Eric Powell, Gary W. Beecham, Liyong Wang, Stephan Züchner, Ioanna Konidari, Gaofeng Wang, Carlos Sing...> ;Annals of Human Genetics. 2010 Mar 1
• 20 citations
  Impulse control disorders arising in 3 patients treated with rotigotine.
  Thomas S. Wingo, Marian L. Evatt, Burton L. Scott, Alan Freeman, Mark Stacy> ;Clinical Neuropharmacology. 2009 Mar 1
• 78 citations
  Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study
  Fabrizio Stocchi, B. Hersh, Burton L. Scott, Paul A. Nausieda, Luigi Giorgi> ;Current Medical Research and Opinion. 2008 Sep 2
• 170 citations
  Pesticide exposure and risk of Parkinson's disease: A family-based case-control study
  Dana B. Hancock, Eden R. Martin, Gregory Mayhew, Jeffrey M. Stajich, Rita Jewett, Mark Stacy, Burton L. Scott, Jeffery M. Vance, William K. Scott> ;BMC Neurology. 2008 Mar 28
• 81 citations
  Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease.
  Dana B. Hancock, Eden R. Martin, Jeffrey M. Stajich, Rita Jewett, Mark Stacy, Burton L. Scott, Jeffery M. Vance, William K. Scott> ;Archives of Neurology. 2007 Apr 1
• 170 citations
  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease
  Karl Kieburtz, Bernard Ravina, Wendy R. Galpern, Barbara C. Tilley, Kathleen M. Shannon, Caroline M. Tanner, G. Frederick Wooten, Robert W. Hamill, Jacob I. Sage, Emil...> ;Neurology. 2007 Jan 2
• 28 citations
  NOS2A and the modulating effect of cigarette smoking in Parkinson's disease.
  Dana B. Hancock, Eden R. Martin, Kenichiro Fujiwara, Mark Stacy, Burton L. Scott, Jeffrey M. Stajich, Rita Jewett, Yi-Ju Li, Michael A. Hauser, Jeffery M. Vance, Willi...> ;Annals of Neurology. 2006 Sep 1
• 696 citations
  Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
  Anthony E. Lang, Steven S. Gill, Nik K. Patel, Andres M. Lozano, John G. Nutt, Richard D. Penn, David J. Brooks, Gary Hotton, Elena Moro, Peter Heywood, Matthew Brodsk...> ;Annals of Neurology. 2006 Mar 1
• Join now to see all

Journal Articles

• Linkage of familial essential tremor to chromosome 5q35  
  Hicks JE, Konidari I, Scott BL, Stajich JM, Ashley-Koch AE, Gilbert JR, Scott WK, Mov. Disord, 1/1/2016
• Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind randonised trial  
  NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, Lancet Neurol, 1/1/2015
• Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience  
  Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators, JAMA Neurol, 1/1/2014
• Natural history of Huntington Disease  
  Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AFD, Biglan KM, Shoulson I, for the Huntington Study Group COHORT Investigators, JAMA Neurol, 1/1/2013
• Design innovations and baseline findings in a long-term Parkinson�s trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson�...  
  Elm, JJ, The NINDS NET-PD Investigators, Mov. Disord., 1/1/2012
• Auditory-perceptual analysis of dysarthria in bilateral striatopallidodentate calcinosis (Fahr�s disease)  
  Jacks A, Haley KL, Scott BL, Jones H, J Med Speech Lang Pathol., 1/1/2012
• Meta-analysis of Parkinson�s disease: identification of a novel locus, RIT2  
  Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Donheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER..., Ann Neurol., 1/1/2012
• Predictors of time to requiring dopaminergic treatment in 2 Parkinson�s disease cohorts  
  Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE on behalf of the Parkinson Study Group DATAOP and PRECEPT Investigators, Mov Disord, 1/1/2011
• A long-term study of istradefylline in subjects with fluctuating Parkinson�s disease  
  Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-007 Study Group, Parkinsonism Relat Disord, 1/1/2011
• Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease  
  Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines ..., Ann Hum Genet., 1/1/2010
• Integrated behavior therapy in the treatment of complicated Tourette�s disorder and its comorbidities  
  Bryson WJ, Edwards CL, Sommer DB, Scott BL, Clin. Case Studies, 1/1/2010
• Impulse control disorders arising in 3 patients treated with rotigotine  
  Wingo TS, Evatt M, Scott B, Freeman A, Stacy M, Clin Neuropharm, 1/1/2009
• Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson�s disease: a randomized, double-blind, non-inferiority crossover study  
  Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Curr. Med. Res. Opin., 1/1/2008
• Pesticide exposure and risk of Parkinson�s disease: a family-based case-control study  
  Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK, BMC Neurology, 1/1/2008
• A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease  
  The NINDS NET-PD Investigators, Neurology, 1/1/2007
• Parkinson�s disease � A form of �Idiopathic parkinsonism�  
  Scott BL, Wake Co. Physician, 1/1/2007
• Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease  
  Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK, Arch. Neurol, 1/1/2007
• A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease  
  The NINDS NET-PD Investigators, Neurology, 1/1/2006
• NOS2A and the modulating effect of cigarette smoking in Parkinson�s disease  
  Hancock DB, Martin ER, Fujiwara K, Stacy MA, Scott BL, Stajich JM, Jewett R, Li YJ, Hauser MA, Vance JM, Scott WK, Ann. Neurology, 1/1/2006
• Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson Disease  
  Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Woo..., Ann. Neurol, 1/1/2006
• Family-based case control study of cigarette smoking and Parkinson disease  
  Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM, Neurology, 1/1/2005
• Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra  
  Noureddine MA, Li YJ, van der Walt JM, Walters R, Jewett RM, Xu H, Wang T, Walter JW. Scott BL, Hulette C, Schmechel D, Stenger JE, Dietrich F, Vance JM, Hauser MA, Mov. Disord, 1/1/2005
• Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism  
  Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, ..., Arch. Neurol., 1/1/2005
• Fibroblast Growth Factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease  
  Van der Walt JM, Noureddine MA, Kittappa R, Hauser MA, Scott WK, McKay R, Zhang F, Stajich JM, Fujiwara K, Scott BL, Pericak-Vance MA, Vance JM, Martin ER, Am. J. Human Genet., 1/1/2004
• A case of combined orthostatic tremor and primary gait ignition failure  
  Myers BH, Scott BL, Clin. Neurol. Neurosurg, 1/1/2003
• Join now to see all

Books/Book Chapters

• The American Psychiatric Publishing Textbook of Geriatric Psychiatry 
  Chapter: Movement disorders 
  Page 231.0 - 240.0Scott BLEditors: Blazer DG, Steffens DC, Busse E.American Psychiatric Publishing, Arlington, VAEdition 3rd,2004
• Neuromethods 
  Chapter: Quantitative analysis of acyl group composition of brain phospholipids, neutral lipids, and free fatty acids. 
  Page 83.0 - 110.0Marcheselli VL, Scott BL, Reddy TS, Bazan NGEditors: Boulton AA, Baker GB, Horrocks LA.Humana Press, Clifton, NJ1987
• Neuromethods 
  Chapter: Quantitative analysis of acyl group composition of brain phospholipids, neutral lipids, and free fatty acids 
  Marcheselli VL, Scott BL, Reddy TS, Bazan NGEditors: Boulton AA, Baker GB, Horrocks LA.Humana Press, Clifton, NJ1987

Abstracts/Posters

• Impulse control disorders arising in three patients treated with rotigotine. Impulse Control Disorders in Parkinson�s Disease Abstract Supplement.
  Wingo TS, Evatt M, Scott B, Freeman A, Stacy M, Mov. Disord., 1/1/2008
• Safety and Tolerability of Istradefylline (KW-6002) in Parkinson�s Disease With Motor Response Complications: Results of the KW-6002-US-018 Study.
  Pourcher E and the 6002-US-018 Clinical Investigator Group, Congress of Parkinson�s Disease and Movement Disorders, Kyoto, Japan, 1/1/2006
• Efficacy of Istradefylline in Parkinson�s Disease Patients Treated With Levodopa With Motor Response Complications: Results of the KW-6002-US-018 Study
  Guttman M and the 6002 US-018 Clinical Investigator Group, 10th International Congress of Parkinson�s Disease and Movement Disorders., Kyoto, Japan, 1/1/2006
• Istradefylline for the Treatment of Motor Response Complications on Levodopa in PD patients: Results of the KW-6002-US-018 Study Focusing on Functional and Motor Impro...
  Fernandez HH and the 6002-US-018, 10th International Congress of Parkinson�s Disease and Movement Disorders, Kyoto, Japan, 1/1/2006
• Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson�s disease.
  Stocchi F, Hersh BP, Earl NL, Scott BL, Mov. Disord, 1/1/2006
• Pesticide use and risk of Parkinson disease: A family-based case-control study.
  Scott WK, Zhang L, Stajich JM, Scott BL, Stacy MA, Vance JM, Mov. Disord., 1/1/2004
• Defining the linkage disequilibrium region containing the Tau gene and identifying haplotype tagging polymorphisms.
  Oliveira SA, Martin ER, Scott WK, Zhang F, Stajich JM, Middleton LT, Roses AD, Scott BL, Fujiwara K, Pericak-Vance MA, Vance JM, Am. J. Human. Genet., 1/1/2003
• Genomic convergence: Identification of candidate genes for Parkinson Disease (PD) using genetic linkage and gene expression in the substantia nigra.
  Hauser MA, Noureddine M, Walter JW, Walters RW, Hulette CM, Schmechel DE, Bembe ML, Stajich JM, Xu H, Martin ER, Scott BL, Stenger J, Li YJ, Jensen R, Scherzer C, Gull..., Am. J. Human Genet., 1/1/2003
• Characterization of Tau association with Parkinson disease.
  Oliveira SA, Zhang FY, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Sm..., Ann. Neurol, 1/1/2003
• Location of common age-at-onset genes in Alzheimer and Parkinson diseases.
  Li YJ, Scott WK, Hedges DK, Zhang FY, Gaskell PC, Stajich JM, Saunders AM, Scott BL, Schemechel DE, Welsh-Bohmer KA, Conneally PM, Gilbert JR, Vance JM, Pericak-Vance ..., Neurobiol. Aging, 1/1/2002
• Identification of candidate genes for Parkinson disease (PD) by the convergence of genetic linkage and association data with gene expression in the substantia nigra.
  Hauser MA, Walter JW, Walters RW, Maready M, Takeuchi S, Segars WP, Hulette CM, Schmechel DE, Bernba ML, Stajich JM, Hauser ER, Martin E, Scott BL, Stenger J, Li YJ, B..., Am. J. Human Genet, 1/1/2002
• Complete genomic screen in familial Parkinson disease.
  Scott WK, Stajich JM, Scott BL, Rogala AR, Booze MW, Ribble RC, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J..., Neurology, 1/1/2001
• Complete genomic screen in idiopathic Parkinson disease
  Scott WK, Stajich JM, Scott BL, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FH, Goetz CG, Small GW, Mastaglia F..., Am. J. Human Genet., 1/1/2001
• Validity of the CS-PFP as a measure of physical functional capacity of those in early/mid-stage Parkinson�s disease
  Schenkman M, Cutson TC, Kuchibhatia M, Scott BL, Cress ME, Gerontologist, 1/1/2001
• Parkin mutations and idiopathic Parkinson disease (PD).
  Scott WK, Rogala AR, Rampersaud E, Stajich JM, Nance MA, Watts RL, Hubble JP, Scott BL, Haines JL, Koller WC, Stern MB, Hiner BC, Jankovic J, Allen FH, Goetz CG, Small..., Am J Human Genet, 1/1/2000
• Exacerbation of stuttering after pallidotomy for Parkinson�s disease.
  Scott BL, Hurwitz B, 6th National Parkinson Foundation International Symposium on Parkinson�s Disease Research., Miami FL, 1/1/1999
• Parkinson�s Disease:Clinical Features in Sibships
  Hubble JP, Weeks CC, Nance M, Watts RL, Koller WC, Stern MB, Colcher A, Ondo W, Jankovic J, Goetz C, Pappart E, Scott WK, Stajich JM, Scott BL, Vance JM, Pericak-Vance MA, Neurology, 1/1/1999
• The alpha-synuclein gene is not a major risk factor in familial Parkinson Disease (PD).
  Yamaoka LH, Scott WK, Stajich JM, Scott BL, Vance JM, Roses AD, Pericak-Vance MA, Annual Meeting of the American Society of Human Genetics., 1/1/1998
• Apolipoprotein E and neural survival.
  Matthew WD, Guyton JR, Scott BL, Strittmatter WJ, Exper Neurol, 1/1/1998
• Exclusion of the alpha-synuclein gene as a major genetic risk factor in idiopathic Parkinson disease (PD).
  Scott WK, Yamaoka LH, Stajich JM, Speer MC, Scott BL, Nance M, Hubble J, Watts RL, Koller W, Jankovic J, Ondo W, Stern MB, Colcher A, Hiner BC, Allen FH, Goetz C, Papp..., Neurology, 1/1/1998
• Apolipoprotein E and Microtubule Dynamics
  Strittmatter WJ, Scott B, DeSerrano V, Roses AD., Keystone Conference, 1/1/1997
• Sumatriptan in the treatment of essential palatal myoclonus.
  Scott BL, Evans RW, Jankovic J, Neurology, 1/1/1996
• Delayed-onset progressive movement disorders after static brain lesions.
  Scott BL, Jankovic J, Neurology, 1/1/1995
• Polyunsaturated fatty acids in retinal development
  Scott BL, Bazan NG, American Oil Chemists Society meeting on Lipid Oxidation, Biloxi, MS, 1/1/1987
• Selective accumulation of docosahexaenoic acid (DHA) in dissociated rod photoreceptor cells during mouse postnatal development
  Scott BL, Moises J, Lolley RN, Bazan NG, Suppl Invest Ophthalmol Vis Sci, 1/1/1987
• Join now to see all

Lectures

• Parkinson�s Disease: Clinical Features 
  1/1/2009
• Update on PD 
  Wilmington - 1/14/2005
• Inherited Ataxias 
  1/7./2005
• Medical Update on PD 
  The Forest at Duke Assembly Hall - 1/20/2005
• Managing PD 
  Raleigh NC - 1/8./2005
• Parkinsonism 
  Wake Med, Raleigh - 1/2./2006
• Restless Legs Syndrome: Understanding, Evaluation, and Management 
  Wilson Medical Center, Wilson NC - 1/3./2006
• Duke Dystonia Course 
  Duke Clinical Research Center - 1/30/2006
• Q & A session 
  Ral. Comm. Hosp. - 1/11/2007
• Medical Treatment of Dystonia 
  Millenium Hotel & Morreene Rd Clinic, Durham NC - 1/28/2007
• Parkinson�s Dis. 
  Morehead City NC - 1/1./2007
• Parkinson�s Disease & LS-1 Creatine Trial 
  Lincoln Comm. Clinic, Durham NC - 1/28/2008
• Nervous System 
  Durham NC - 1/18/2008
• What Does a Neurologist Do? 
  1/2./2008
• Diagnosis & Management of PD & Parkinsonian Syndromes 
  Danville Reg. MC - 1/19/2008
• Tetrabenazine and CoQ10 Clinical Trials 
  Wake Forest UMC, Winson-Salem NC - 1/25/2008
• Tetrabenazine & Huntington’s Dis 
  Duke Ral. Hosp - 1/14/2009
• Cervical Dystonia 
  1/6./2009
• PD and Parkinson�s Plus Syndromes 
  1/25/2009
• Brain 
  Durham NC - 1/3./2009
• Tetrabenazine & Clinical Trials 
  1/27/2009
• Current Approaches in Treating Parkinson�s Disease 
  Myrtle Beach, SC - 1/11/2009
• Treatment of Parkinson�s Disease 
  1/25/2009
• PD & the Use of Deep Brain Stimulation 
  1/14/2009
• DBS in Movement Disorders 
  1/20/2009
• Join now to see all

Other

• Ph.D. Thesis: The Three Dimensional Structure of Visual Pigment from Bullfrog Disk Membranes. 
  
  1/1/1984